“Endometriomas are among the most common forms of endometriosis, impacting millions of women. The presentation of data that is foundational to our EndoCheckSM offering at this distinguished conference is a major milestone for our plan to launch the first noninvasive diagnostic test for this debilitating disease,” said
Details of the poster presentation are as follows:
Poster Title: | A Protein Biomarker Test and Artificial Intelligence-Based Algorithm for Ovarian Endometriosis |
Author: | |
Abstract #: | 2066 |
Poster #: | LB-F-04 |
Date: | |
Time: | 9:00 – |
Session: | Late Breaking |
The abstract was co-authored by Aspira’s Research and Development team and the Oxford Endometriosis Care and Research (CaRe) Centre, a collaboration between Oxford University Hospitals and the
SRI, established in 1953, is an international society with over 900 members representing 35 countries. SRI strives to advance reproductive health for all through outstanding basic, translational, and clinical science; training and mentoring future generations of investigators; and by promoting excellence in reproductive sciences globally (www.sri-online.org).
About Aspira Women’s
Aspira Women’s
OvaWatchSM and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is comprised of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.
Forward-Looking Statements
This press release may contain forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including those relating to the timing and completion of any products in the pipeline development and other statement that are predictive in nature. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release and other factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering. These and additional risks and uncertainties are described more fully in the company’s filings with the
Investor Relations Contact:
Chief Financial Officer
Aspira Women’s Health
Investors@aspirawh.com
Source:
2024 GlobeNewswire, Inc., source